About Us
Transforming the Paradigm to improve lives
We leverage advanced artificial intelligence (AI) to transform drug development.
The pharmaceutical industry faces significant challenges: development timelines often exceed a decade, costs continue to rise, and many diseases still lack effective treatments.
Our AI platform addresses these inefficiencies by applying data-driven insights across the entire development process. We enhance target identification, advance the understanding of disease biology, and optimize clinical trial design to increase the probability of success.
Our objective is to accelerate the delivery of new therapies to market, with a focused commitment to addressing unmet medical needs.
Mission
Focus On Unmet Medical Needs and Achieve Clinical Value
Vision
To Become the Most Dynamic and Innovative AI -empowered Pharmaceutical Company
leadership
Tom Du, MD, PhD
Founder, Chief Executive Officer
Tom Du, MD, PhD
Founder, Chief Executive Officer
Dr.Du received his Ph.D. from McGill University in Canada, followed by two years of postdoctoral training at Harvard University under Professor Frank Austen, a distinguished member of the National Academy of Sciences.
Commencing in 1994, Dr. Du served for seven years as a new drug reviewer for the U.S. FDA. Following his tenure at the FDA, he held significant leadership positions, including Director of The Registration Division at United Healthcare Corporation in the United States and Senior Director of Clinical and Registration at Hutchison Whampoa Pharmaceuticals.
As Chief Pharmaceutical Development Consultant at Humphrey Medical Consulting Co., LTD., Dr. Du led a multinational and multidisciplinary new drug development team, successfully completing over 100 new drug development and application projects.
Charles Lee, MD, PhD
Co-founder, Chief Medical Officer
Charles Lee, MD, PhD
Co-founder, Chief Medical Officer
Dr. Lee earned his Master's degree in Hospital Administration and a Doctor of Public Health degree from the University of Alabama Birmingham. He completed a three-year residency at the University of Chicago Medical Center, obtaining both the American Physician license and the American Clinical Pathology Specialist certification.
Dr. Lee previously served as a Senior Medical Reviewer for the U.S. Food and Drug Administration (FDA). He possesses extensive experience in Phase I-IV global clinical trials across various therapeutic areas, including oncology, immunotherapy, anti-inflammatory, gastrointestinal, and gynecological diseases.
He has led hundreds of clinical trials and more than 30 new drug filings worldwide, developing comprehensive solutions for global drug development, regulatory registration, clinical strategy, and risk management.
Kevin Wang, MBA
Chief Business Officer
Kevin Wang, MBA
Chief Business Officer
Graduated from the University of Miami with an MBA and a Master of Biostatistics. He has more than 15 years of experience in the pharmaceutical industry and more than 5 years of business development experience. He has worked in US-listed pharmaceutical companies and pharmaceutical consulting companies for many years, and has worked in AOB and Humphrey Pharmaceutical Consulting, serving as Deputy General Manager of Business Development and Assistant to the president. He is familiar with the daily operation of innovative pharmaceutical companies and has extensive experience in business cooperation, patent planning and technology transfer of pharmaceutical projects.
James Diao, MSc, PRINCE2
VP, Investor Relations
James Diao, MSc, PRINCE2
VP, Investor Relations
James received a B.A. in Marketing and Management from Newcastle University Business School and holds an MSc. in Project Management from the University of Manchester, in addition to being PRINCE2 certified by the UK government. With more than a decade of experience in the healthcare sector, he began his career at Omnicom Health Group AP as a Head of Operation and Executive Assistant, delivering market consulting services to many globally recognized MNCs such as MSD, Pfizer, BMS and Novartis. Prior to joining Evergreen, James served as Vice President at Continental Capital, where he accumulated extensive expertise in pharmaceutical market research and private equity investments.
Charlie Cao, MS
Director of Corporate Finance
Charlie Cao, MS
Director of Corporate Finance
Charlie holds a master’s degree in Economics from the China University of Geosciences and studied Financial Management at HeJun Business School. Since joining Evergreen, he has played a key role in finishing A+ round funding and completing several debt financings. Prior to Evergreen, he served as a Financing Supervisor at Shenzhen Dongyin Financial Holding and as an Investment Director at China Aviation Future and responsible for managing Fund of Funds investments, conducting analysis and executing investments in more than 20 private equity funds. During his 8-years career in investment and financing field, he participated in or led funding totaling over $140 million.
Patrick McGrath, PhD
VP, Clinical Operation
Patrick McGrath, PhD
VP, Clinical Operation
PhD at University of Missouri, rich experience in clinical design, operation, and regulations in multiple therapeutic areas, professional knowledge of prescription drugs regulations in the U. S., is responsible for implementing the company's clinical trials.
Shanshan Li, PhD
Senior Director, CMC and Regulatory Affairs
Shanshan Li, PhD
Senior Director, CMC and Regulatory Affairs
Bachelor of Chemistry, Tsinghua University; Doctor of Pharmacy, Rutgers University, New Jersey, USA; With nearly 10 years of CMC working experience in the pharmaceutical industry, I am proficient in leading the whole industry chain process of topic selection and project approval, formula research and development, scale-up production, FDA application, commercial batch production and listing of products.
Bill Wang, PhD
Director of AI Bioinformatics
Bill Wang, PhD
Director of AI Bioinformatics
Bill graduated from Beijing Normal University, received his Ph.D. in Biology from Uppsala University, and postdoctoral fellow at Kanarinska Institutet, Sweden; He was a former Director of the Bioinformatics Centre at the University of Melbourne, and is a scientist with many years of experience in bioinformatics engineering and genomics research.
scientific advisory board
Florence Houn
Clinical Development Consultant of Anticancer and Other Drugs
Florence Houn
Clinical Development Consultant of Anticancer and Other Drugs
Dr. Houn is a former outstanding leader of FDA, having served as the Office Director of CDER, CBER, and CDRH for 15 years. She also served as executive in MNCs, and is a former professor at Johns Hopkins University and an oncologist. Dr. Houn is currently a clinical development consultant of anticancer and other drugs in Evergreen.
James Martin
Clinical Development Consultant in Basic Science
James Martin
Clinical Development Consultant in Basic Science
Dr. Martin is a renowned respiratory specialist, former chief of internal medicine at McGill University, former director of the Respiratory Disease Institute, and a leading expert in asthma and COPD, especially in asthma pathophysiology research. Currently he serves as a consultant of Evergreen on basic science and clinical trials of respiratory diseases.
Paolo Baroldi
Clinical Development Consultant of Immunology
Paolo Baroldi
Clinical Development Consultant of Immunology
PhD in Clinical Pharmacology, Diploma from Harvard Business School Executive Education. An outstanding physician and clinical pharmacologist with more than 35 years of experience in pharmaceutical industry and drug development led the R&D of 25 new drugs including epirubicine, imatinib. Expertise in a wide variety of therapeutic areas.
Richard Moore
Clinical Development Consultant in Oncology
Richard Moore
Clinical Development Consultant in Oncology
Dr. Moore is the Chair of Department of Gynecologic Oncology at the University of Rochester Medical Center. Former chair of the Department of Gynecologic Oncology at Brown University. He is an internationally recognized expert who uses biomarkers to detect ovarian cancer. Dr. Moore has a strong professional relationship with Evergreen and currently serves as the clinical development consultant in oncology.
